



King's Research Portal

DOI:

10.1186/s13063-019-3459-4

Document Version Publisher's PDF, also known as Version of record

Link to publication record in King's Research Portal

Citation for published version (APA):

Murphy, G. R. F., Logan, M., Smith, G., & Sivakumar, B. (2019). RADIATE - Radial Dysplasia Assessment, Treatment and Aetiology: Protocol for the development of a core outcome set using a Delphi survey. *Trials*, 20(1), 1-6. Article 339. Advance online publication. https://doi.org/10.1186/s13063-019-3459-4

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Download date: 13. Jan. 2025

STUDY PROTOCOL

Open Access

RADIATE – Radial Dysplasia Assessment, Treatment and Aetiology: protocol for the development of a core outcome set using a Delphi survey



George R. F. Murphy^{1,2*}, Malcolm Logan², Gill Smith¹ and Bran Sivakumar¹

Abstract

Background: Radial dysplasia (RD) is a disfiguring, potentially disabling congenital upper limb anomaly. Multiple surgical techniques are in current use, with little agreement on the optimal treatment approach. At present, no core outcome set exists specifically for RD, and the literature is dominated by retrospective case series. A recent systematic review by this group demonstrated significant heterogeneity on which outcomes are measured and how they are measured.

Methods/design: The RADIATE study will conduct a three-round online Delphi process, involving adult RD patients, the parents of children with RD, hand surgeons and hand therapists. The initial list of outcomes was drawn from our recent systematic review and will be supplemented by suggestions from the stakeholder groups. Following the Delphi process, outcomes that meet the consensus in definition will be ratified at a final consensus meeting. We will then follow the COSMIN guidelines to select outcome measurement instruments. Where appropriate, these will overlap with the outcome measures specified in the forthcoming standard set for congenital upper limb anomalies published by the International Consortium for Health Outcomes Measurement.

Discussion: The Radial Dysplasia Assessment, Treatment and Aetiology (RADIATE) study aims to address the uncertainty in the treatment of RD, and to begin to answer the question 'What is the most appropriate treatment of the forearm and hand for children with RD?' by establishing a core outcome set.

Trial registration: COMET initiative study, 902. Registered in May 2016.

Keywords: Radial dysplasia, Congenital upper limb anomalies, core outcome set, Congenital hand surgery

Background

Radial dysplasia (RD) is a disfiguring, potentially disabling congenital upper limb anomaly, affecting approximately 1 in 8000 births [1–3]. It is characterised by the variable absence or hypoplasia of the pre-axial upper limb skeleton (radius and thumb) and soft tissues [4]. Affected children have a phenotype ranging from isolated thumb hypoplasia to complete absence of the thumb and radius, with severe ulnar bowing, elbow stiffness and

humeral hypoplasia. Children may be unilaterally or bilaterally affected. Known causes include spontaneous mutations, teratogenic drugs and syndromes such as Holt–Oram syndrome, vertebral, anal, cardiac, tracheoesophageal, renal and limb (VACTERL) anomalies or Fanconi anaemia, although approximately 50% of cases are of unknown aetiology. Children without associated major comorbidities can expect a normal lifespan.

Globally, several treatment techniques to address this wrist deformity are in common use at specialist centres, including centralisation [5] or radialisation [6] of the ulna, either with or without prior soft-tissue distraction [7], and the microvascular transfer of a toe joint to act as a radial buttress to the wrist [8]. The surgical

²Randall Division of Cell and Molecular Biophysics, Guy's Campus, King's College London, London SE1 1UL, UK



^{*} Correspondence: george.murphy@gosh.nhs.uk

¹Department of Plastic Surgery, Great Ormond Street Hospital for Children, London WC1N 3JH, UK

Murphy et al. Trials (2019) 20:339 Page 2 of 6

treatment of the soft tissues is highly variable. A recent systematic review by our group found that patients suffer poor forearm growth and some degree of recurrent radial wrist deviation, whether treated surgically or conservatively [9]. Currently, there is no core outcome set (COS) specifically for RD, although a generalised standard set for congenital upper limb anomalies is due to be published soon [10]. Measuring outcomes is further complicated because the limbs change during growth, necessitating follow-ups until skeletal maturity before the final outcome can be assessed.

The Radial Dysplasia Assessment, Treatment and Aetiology (RADIATE) study aims to address the uncertainty in the treatment of RD, and to begin to answer the question 'What is the most appropriate treatment of the forearm and hand for children with RD?' by establishing a COS.

Selection of outcomes for use in clinical studies of RD

Clinical studies, whether interventional or observational, should have prospectively defined primary and secondary outcomes that answer the questions posed by the hypothesis. However, for existing studies of RD, the outcomes measured are numerous and highly variable between studies. The techniques for measuring many outcomes are also poorly defined, making it difficult to compare studies or synthesise their results in a metanalysis. It is also unclear how relevant, if at all, these outcomes are to patients.

Outcome reporting bias

Another problem, especially in the surgical literature, is outcome reporting bias [11], where a large number of outcomes are measured but only those that show interesting or positive results are reported. This presents a biased view of the results of a trial. As the number of tests increases, so does the risk of results arising by chance erroneously being labelled as significant.

Core outcome sets

The development of a COS is one way to overcome these problems. Such a prospectively defined group of outcomes is the minimum dataset that trials for a given condition should report. For paediatric conditions, they are ideally developed with patient and family involvement. Prospectively specifying the outcomes and how they are measured should prevent cherry-picking of positive results and it should standardise studies, allowing comparison and synthesis of their results. When developed with patients and their families, they also provide reassurance that the outcomes are relevant to patients.

Scope, aim and objectives

Aim

The aim of this study is to develop an initial COS suitable for assessing treatment outcomes after any form of treatment, including conservative management, for congenital upper limb anomalies in patients with RD.

Scope

The COS is designed for use in both research and routine clinical care, in any health-care system treating congenital upper limb anomalies due to RD. It should cover children of all ages and adults, and should apply to all interventions for congenital upper limb anomalies in patients with RD.

Objectives

The specific study objectives are: (1) to list all outcomes previously reported in studies of the treatment of RD, identified through a systematic review of the literature, (2) to prioritise outcomes from the overall perspective of patients, parents and clinicians, (3) to compare outcomes that are important to patients and parents with those that are important to clinicians and (4) to integrate these outcomes into a combined COS.

Methods/design

Systematic review

We recently published a systematic review of the long-term outcomes of both surgical and conservative treatments for RD [9]. This was prospectively registered with the PROSPERO database (CRD42016036665) and conducted using the Cochrane highly sensitive search strategy. We searched Medline and Embase via OvidSP, PubMed, Cochrane, ClinicalTrials.gov and the WHO International Clinical Trials portal for published and unpublished studies. Searches were not restricted by date or language. From all studies identified that reported outcomes for RD treatment, we extracted a list of outcomes measured for RD following the process in the COMET handbook [12] (Section 2.7.1.2), which will form the starting point for our Delphi process.

Identification of outcomes important to patients, parents and clinicians

Overview

To achieve consensus on a COS for RD within and between groups, we propose to use an online Delphi process, adapted and simplified from the protocol laid out by Harman et al. [13]. This will include four groups of participants:

- RD patients aged over 16
- parents of RD patients aged under 16
- hand therapists who treat RD patients

Murphy et al. Trials (2019) 20:339 Page 3 of 6

• hand surgeons who treat RD patients

These groups were chosen so that patient and family perspectives will have the same status as surgical and therapist perspectives. We aim to make the groups of similar size. Patient and parent groups will be drawn from across the UK, and clinician groups drawn from specialist centres internationally. The study will be managed from Great Ormond St Hospital in London, and participants will be recruited via email by the central research team, following identification by participating specialist centres worldwide. The Delphi process will be administered using the secure software DelphiManager at the University of Liverpool. The study process is summarised in Fig. 1 and Additional file 1.

Identification of potential outcomes

Our initial outcome list was generated from the outcomes identified during our systematic review. We included all outcomes that we identified in the global literature on RD treatment. Composite outcome scores have been split into their component parts, where possible. The outcome list will be presented thematically, by outcome domain. Outcomes will be described using lay language, then medical language beneath, with a diagram or picture as required. The draft outcome list will be piloted with members of all stakeholder groups before use to ensure it is easily understood and clear.

Participants and stakeholder selection

We aim to recruit the patient and parent groups via specialist centres across the UK, and the therapist and surgeon groups from global specialist centres. All participants will be required to be proficient with spoken and written English, and to have access to a computer and internet connection.

Delphi process

Round 1: initial ranking and finalising outcomes

Participant identification centres have been identified by the review authors. Potential participants will be identified by each centre locally, then invited to participate in the Delphi process by the central research team at Great Ormond St. Those who agree will be invited to register with DelphiManager, then sent an email linking to an online survey. Each identified outcome will be listed thematically by outcome domain. An open question at the end will allow participants to nominate important missing outcomes. They will be asked to rank each outcome 1-9, where 1-3 are 'not important', 4-6 are 'important but not critical' and 7-9 are 'critical'. A review author (GM), who will not participate in the survey, can see who has completed the online survey. Participants will be given 3 weeks to complete the survey. Reminder emails will be sent after 1 and after 2 weeks.

	STUDY PERIOD					
	Enrolment	Allocation	Post-allocation		Close-out	
TIMEPOINT**	Nov 2018 – Jun 2019	Jun 2019	Jun 2019	Jul 2019	Aug 2019	Sep 2019
ENROLMENT:						
Eligibility screen	Х					
Informed consent	Х					
Allocation		Х				
INTERVENTIONS:						
Delphi round 1			Х			
Delphi round 2				Х		
Delphi round 3					Х	
Consensus meeting						Х

Fig. 1 SPIRIT figure; schedule of enrolment, interventions and assessments

Murphy et al. Trials (2019) 20:339 Page 4 of 6

Analysis of round 1

Newly suggested outcomes will be reviewed by two review authors (GM and BS) to ensure they are genuinely novel, then combined and added to the round 2 questionnaire accordingly. The results will be analysed by participant group and as an overall summary, which will include the number participating and the distribution of scores per outcome. Outcomes meeting the consensus out definition will be excluded from the round 2 questionnaire. Individual participation in round 2 will be contingent upon completing the survey in round 1.

Round 2

Participants will again be contacted by email with a link to the online survey. For each previously scored outcome, they will be presented with a histogram summary of the responses for each group and for all groups combined, plus a reminder of their previous score. They will then be asked to re-score each outcome, again from 1 to 9, and then to score any newly suggested outcomes identified in round 1. Participants will be given 3 weeks to complete the round 2 survey, with a reminder email being sent after 1 and after 2 weeks.

Analysis of round 2

The results will be analysed both by participant group and as an overall summary, which will include the number participating and the distribution of scores per outcome. Outcomes meeting the consensus out definition will be excluded from the round 3 questionnaire. Individual participation in round 3 will again be contingent upon completing the survey in round 2.

Round 3

Participants will again be contacted by email with a link to the online survey. For each outcome they will be presented with a histogram summary of the responses for each group and for all groups combined, plus a reminder of their round 2 score. They will then be asked to rescore each outcome, again from 1 to 9. Participants will be given 3 weeks to complete the round 3 survey, with a reminder email being sent after 1 and after 2 weeks.

Analysis of round 3

The results will be analysed both by participant group and as an overall summary, which will include the number participating and the distribution of scores per outcome. Outcomes will be classified as consensus in, consensus out or no consensus using the criteria from Harman et al. [13], as summarised in Table 1. The distribution of scores and consensus result for each outcome will be displayed by group and overall and used to structure the final consensus meeting.

Consensus meeting

A final consensus will be reached during a consensus meeting, which may involve a mixture of face-to-face and teleconference participation. All participants in the Delphi survey will be invited. All participants will receive the results of round 3 in advance, presented by group and overall. We will then follow the COSMIN guidelines to select outcome measurement instruments. To avoid duplication of effort by patients, clinicians and researchers, where outcomes overlap, we will use measurement instruments from the International Consortium for Health Outcomes Measurement (ICHOM) standard set for congenital upper limb anomalies. The final COS will be published in a peer-reviewed journal.

Statistical analysis and sample size

Scores for each item will be presented as a histogram of responses, and the percentage of responses in each group (1–3, 4–6 and 7–9) calculated. This will be done by individual stakeholder group and for all groups combined. As there is no standard model for the sample size required for a Delphi process, we will aim for between 10 and 15 participants per group, with the patient and parent groups covering patients with varying degrees of disease severity and different ages.

Discussion

There is currently no COS specifically for RD. This study seeks to develop one, with the involvement of a wide range of participants, to ensure maximal acceptability to both patients and clinicians.

As with any project, this study has limitations. The long list of outcomes has been developed from a comprehensive systematic review, but it is possible that we have missed relevant outcomes, especially those not represented in the existing literature. Supplementing the initial list with qualitative interviews is one approach suggested in the COMET handbook [12], but is beyond

Table 1 Definition of consensus (after Harman et al. [13])

Table 1 Definition of consensus (after Harman et al. [15])				
Consensus classification	Description	Definition		
Consensus in	Consensus that the outcome should be included in the core outcome set	70% or more of the participants score it as 7–9, and <15% of the participants score it as 1–3		
Consensus out	Consensus that the outcome should not be included in the core outcome set	70% or more of the participants score it as 1–3, and $<$ 15% of the participants score it as 7–9		
No consensus	Uncertainty about the importance of the outcome	Any other outcome		

Murphy et al. Trials (2019) 20:339 Page 5 of 6

the resources of this project. By allowing all stakeholders to suggest further outcomes in round 1 of the Delphi process, we aim to reduce this risk to acceptable levels, but must concede that this approach "does not have the same standing as the knowledge generated by [qualitative] research" [12].

The choice of stakeholders has been informed by current treatment protocols for RD. Primary surgery typically happens before the patient is aged 2, meaning that parents are the key early decision makers, whose views we wish to include. We aim to reflect the independent views of RD children both by encouraging parents to involve their children as much as is age and developmentally appropriate in completing the survey, and by including a separate group of RD patients aged over 16. Together with the international groups of surgeons and hand therapists, we believe this provides a balanced perspective on RD treatment.

Where outcomes overlap, we will use measurement instruments from the recently developed ICHOM congenital upper limb anomalies standard set [10], so that patients and clinicians are not unduly burdened by multiple measurements for an outcome. This standard set includes measurement instruments that were chosen through a methodologically robust Delphi process, informed by patient focus groups and the literature.

We hope that this outcome set will make the interpretation, comparison and synthesis of future studies easier.

Study status

The study protocol is version 1.0 (18 July 2018). Recruitment commenced on 28 November 2018 and is expected to be complete before June 2019. The study is expected to take 3 months once recruitment is complete.

Additional file

Additional file 1: SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*. (DOC 121 kb)

Abbreviations

COS: Core outcome set; ICHOM: International Consortium for Health Outcomes Measurement; RADIATE: Radial Dysplasia: Assessment, Treatment and Aetiology; RD: Radial dysplasia; VACTERL: Vertebral, anal, cardiac, tracheoesophageal, renal and limb anomalies

Acknowledgements

The authors are grateful to Professor Paula Williams and the DelphiManager team at the University of Liverpool for their advice on study design and conduct.

Authors' contributions

GM conceived the study and wrote the manuscript. GM, ML, GS and BS secured ethical approval for the study, contributed to the study design, and read and approved the final manuscript.

Authors' information

GM is a plastic surgery registrar, a PhD student in ML's lab at King's College London and the British Society for Surgery of the Hand research fellow at Great Ormond St Hospital, London. ML is Professor of Regenerative Biology at the Randall Centre, King's College London. GS and BS are consultant congenital hand surgeons at Great Ormond St Hospital, London.

Funding

This study is funded by a PhD award to George Murphy from the British Society for Surgery of the Hand. Professor Logan is in receipt of a research grant from the Medical Research Council. Neither funder was involved in the design of the study, nor will they be involved in the collection, analysis or interpretation of data or the writing up of the final manuscript. The study is sponsored by King's College London, which reviewed and approved the protocol prior to issuing sponsor approval. The sponsor representative is Professor Reza Rezavi, rezarazavi@kcl.ac.uk

Availability of data and materials

The datasets produced, used and analysed during the current study will be available in anonymised form at individual participant level from the corresponding author on reasonable request, after publication of the final study results.

Ethics approval and consent to participate

This study will be conducted in accordance with the Declaration of Helsinki. Implied informed consent will be sought from all participants prior to entry into the study. Ethical approval was granted by the London Queen Square research ethics committee on 12 September 2018 (18/LO/1561).

Consent for publication

Not applicable (no individual participant data are included within this manuscript).

Competing interests

The authors declare that they have no competing interests.

Received: 26 October 2018 Accepted: 20 May 2019 Published online: 10 June 2019

References

- Ekblom AG, Laurell T, Arner M. Epidemiology of congenital upper limb anomalies in 562 children born in 1997 to 2007: a total population study from stockholm, sweden. J Hand Surg. 2010;35(11):1742–54.
- Giele H, Giele C, Bower C, Allison M. The incidence and epidemiology of congenital upper limb anomalies: a total population study. J Hand Surg. 2001;26(4):628–34.
- Koskimies E, Lindfors N, Gissler M, Peltonen J, Nietosvaara Y. Congenital upper limb deficiencies and associated malformations in Finland: a population-based study. J Hand Surg. 2011;36(6):1058–65.
- Goldfarb CA, Klepps SJ, Dailey LA, Manske PR. Functional outcome after centralization for radius dysplasia. J Hand Surg. 2002;27(1):118–24.
- Lamb DW. Radial club hand. A continuing study of sixty-eight patients with one hundred and seventeen club hands. J Bone Joint Surg Am. 1977; 59(1):1–13.
- Buck-Gramcko D. Radialization for radial club hand. Tech Hand Up Extrem Surg. 1999;3(1):2–12.
- Kessler I. Centralisation of the radial club hand by gradual distraction. J Hand Surg. 1989;14(1):37–42.
- Vilkki SK. Distraction and microvascular epiphysis transfer for radial club hand. J Hand Surg. 1998;23(4):445–52.
- Murphy GRF, Logan MPO, Smith G, Sivakumar B, Smith P. Correction of "Wrist" Deformity in Radial Dysplasia: A Systematic Review and Meta-Analysis. J Bone Joint Surg Am. 2017;99(24):2120–6.
- ICHOM congenital hand group: ICHOM core outcome set Congenital Hand Malformations. In. https://www.ichom.org/portfolio/congenital-upperlimb-anomalies/. Accessed 5 June 2019.
- Chan AW, Altman DG. Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors. Bmj. 2005; 330(7494):753.

Murphy et al. Trials (2019) 20:339 Page 6 of 6

 Williamson PR, Altman DG, Bagley H, Barnes KL, Blazeby JM, Brookes ST, Clarke M, Gargon E, Gorst S, Harman N, et al. The COMET Handbook: version 1.0. Trials. 2017;18(Suppl 3):280.

 Harman NL, Bruce IA, Callery P, Tierney S, Sharif MO, O'Brien K, Williamson PR. MOMENT—Management of Otitis Media with Effusion in Cleft Palate: protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. Trials. 2013;14:70.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

